Walleye Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Walleye Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,300	Closed	-$207K	–	1104
2020 Q1	$207K	Sell	2,300 -15,300	-87%	-$1.5M	0.05%	433
2019 Q4	$1.9M	Buy	17,600 +14,800	+529%	+$1.58M	0.12%	212
2019 Q3	$274K	Sell	2,800 -10,500	-79%	-$1.18M	0.02%	1017
2019 Q2	$1.74M	Sell	13,300 -3,000	-18%	-$387K	0.19%	121
2019 Q1	$2.2M	Buy	+16,300	New	+$2.03M	0.36%	30

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Walleye Capital's ALXN Position: Q3 2021 in Review

Walleye Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 66,350 shares — an estimated $12.2K sold.

Walleye Capital first reported a position in ALXN in Q3 2018 and held it in 10 quarters. The position peaked at $1.99M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Walleye Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Walleye Capital sold 66,350 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12.2K.
Walleye Capital first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 10 quarters.
Walleye Capital's Alexion Pharmaceuticals position peaked at $1.99M in Q4 2019.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Walleye Capital's 13F filing for Q3 2021, filed 15 Nov 2021.